thought call rais
estim continu commerci execut
strong commerci execut set like out-performance
balanc pipelin option could drive addit upsid
consist consensu expect product revenu vertex
deliv anoth strong quarter rais revenu guidanc remaind
could see rel softer number remain
confid strength cystic fibrosi cf franchis drive top
bottom line growth call manag outlin strategi capit
deploy compani grow cash reserv highlight non-cf
program data next year potenti beta-thalassemia/ sickl
cell like focu extern intern pipelin reinvestmenta
strategi could diversifi revenu cf sale view vertex focu
earli stage fit well compani profil believ vertex
grow cash flow afford greater select pipelin option
burn need buy revenu gilead given like
approv elexacaftor-bas tripl next year overal continu
believ vertex best growth profil among large-cap name given
larg opportun cf coupl pipelin option maintain
vertex top-pick larg cap biotech sector reiter
outperform rais tp
valuat risk valu share use sum-of-the-part sotp
dcf analysi assum wacc tvgr result tp
increas tp ep estim
driven increas revenu cf risk clinical/development
pipelin product fail regulatori fda/ema approv product
commerci market product sell well predict price inabl
achiev price assumpt market risk
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
vertex engag develop commerci
therapeut rare diseas includ main franchis cystic
price jul rate outperform target price analyst evan seigerman
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
scenario assum dcf valu
share cut sg respect also
assum regulatori approv tripl combin
us ou assum posit proof-of-concept data next
gener cf asset also assum posit
data updat pipelin asset
grey sky scenario model less credit triplet
lower probabl success reflect increas risk
compani face meaning setback
pipelin updat look cf franchis vertex recent file nda
tripl submiss ema expect recal
vertex expand label recent symdeko children age year
orkambi australian children age year kalydeco australian children age
month submiss eu symdeko children age year
plan
switch non-cf pipelin vertex expect clinic data
antitrypsin franchis peopl two mutat gene
therapi crispr-partn franchis vertex dose first patient sickl
cell diseas first patient dose beta thalassemia occur final vertex
initi phase studi evalu treatment focal
model adjust increas estim orkambi
symdeko follow strong quarter increas
revenu guidanc market penetr driven model result higher orkambi
symdeko revenu throughout forecast modestli reduc kalydeco
estim reflect perform seen throughout
forecast oper expens assumpt rel unchang minor
chang driven margin assumpt appli updat revenu forecast
forecast dilut ep figur
figur vertex quarterli annual ep usd
profit loss tax
cog revenu
 revenu
sg revenu
valuat price target base base-cas dcf analysi
assum wacc termin growth rate fulli dilut share
outstand vertex experienc commerci regulatori organ
support standard-of-car cystic fibrosi patient around world
substitut epidemiolog cf well understood larg patient
registri exist mani compani major market allow us quantifi
address market vertex ip protect commerci exclus expect
persist throughout forecast period account risk-mitig factor
valuat assumpt via wacc forecast cash flow
account known expect product launch patent expir competit
threat current portfolio pipelin beyond forecast period appli
termin growth rate cash flow expect vertex continu invest life-
cycl manag cf portfolio busi develop effort success
gener increment revenu rate greater eros long-term
sotp analysi base sopt dcf driven mainli vertex cf market drug
includ tripl also includ risk-adjust sale potenti
reimburs uk franc combin unalloc
corpor expens net cash sotp dcf valu
compani mention price
